1. Home
  2. PRZO vs ONCO Comparison

PRZO vs ONCO Comparison

Compare PRZO & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ParaZero Technologies Ltd.

PRZO

ParaZero Technologies Ltd.

HOLD

Current Price

$0.49

Market Cap

18.6M

Sector

N/A

ML Signal

HOLD

Logo Onconetix Inc.

ONCO

Onconetix Inc.

HOLD

Current Price

$0.31

Market Cap

755.3K

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRZO
ONCO
Founded
2014
2018
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.6M
755.3K
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
PRZO
ONCO
Price
$0.49
$0.31
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
539.3K
2.7M
Earning Date
03-26-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
22.80
EPS
N/A
N/A
Revenue
N/A
$815,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$0.07
52 Week High
$2.15
$7.65

Technical Indicators

Market Signals
Indicator
PRZO
ONCO
Relative Strength Index (RSI) 25.60 34.11
Support Level N/A N/A
Resistance Level $0.82 $0.86
Average True Range (ATR) 0.05 0.05
MACD -0.01 -0.00
Stochastic Oscillator 2.72 2.28

Price Performance

Historical Comparison
PRZO
ONCO

About PRZO ParaZero Technologies Ltd.

ParaZero Technologies Ltd operates as an aerospace defense company focused on the development of smart, autonomous solutions for the manned and unmanned aerial systems (UAS) industry. The Company develops, manufactures, markets, and sells counter-UAS net-launching platforms designed to protect against hostile drones in both battlefield and urban environments, precision aerial delivery systems for military applications, and smart, autonomous parachute safety systems designed to enable safe flight operations over populated areas and beyond visual line-of-sight. The Company sells its products internationally.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

Share on Social Networks: